Comprehensive Modeling and Discovery of Mebendazole as a Novel TRAF2- and NCK-interacting Kinase Inhibitor. (2016)

Peer-Reviewed Study · Zhi Tan; Lu Chen; Shuxing Zhang · September 21, 2016

Zhi Tan et al., 2016-09-21: Computational modelling over 1,448 FDA-approved drugs followed by kinase assays identifying mebendazole as a TNIK inhibitor, a Wnt-pathway target in colorectal cancer.

Upon experimental evaluations, we discovered that mebendazole, an approved anthelmintic drug, could selectively inhibit TNIK kinase activity with a dissociation constant Kd = ~1 μM.

Zhi Tan et al., 2016-09-21: Computational modelling over 1,448 FDA-approved drugs followed by kinase assays identifying mebendazole as a TNIK inhibitor, a Wnt-pathway target in colorectal cancer. Study type: in silico modelling plus biochemical kinase assay. N: not applicable. Country: USA (MD Anderson Cancer Center, Houston). Dose: Kd about 1 micromolar. Funder: US NIH R01 GM070737. Declared conflicts: no COI statement in the record. Comparator: the screened drug library.